LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

LLY

1,022.7

+0.26%↑

JNJ

246.77

+0.74%↑

ABBV

224.2

-1.89%↓

NVS

163.46

-1.15%↓

MRK

121.78

+0.14%↑

Начало・Списък с акции・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

43.05 1.65

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

41.78

Максимум

43.18

Ключови измерители
By Trading Economics
Приходи	-6.2M -91M
Марж на печалбата	-867.293
Служители	316
EBITDA	4M -90M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+29.38% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-25M 3.2B
Предишно отваряне	41.4
Предишно затваряне	43.05

Настроения в новините

By Acuity

50%

165 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

34.81 / 38.24 Подкрепа & съпротива

Xenon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.02.2026 г., 23:47 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

19.02.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over Potential U.S. Strike on Iran -- Market Talk

19.02.2026 г., 23:39 ч. UTC

Придобивния, сливания и поглъщания

Swiss Re Corporate Solutions to Buy QBE Insurance's Global Trade Credit and Surety Business >SREN.EB

19.02.2026 г., 23:38 ч. UTC

Печалби

Samsung Fire & Marine Insurance 2025 Net KRW2.020T Vs. Net KRW2.077T >000810.SE

19.02.2026 г., 23:38 ч. UTC

Печалби

Samsung Fire & Marine Insurance 2025 Oper Pft KRW2.659T Vs. Pft KRW2.650T >000810.SE

19.02.2026 г., 23:38 ч. UTC

Печалби

Samsung Fire & Marine Insurance 2025 Rev KRW24.779T Vs. KRW22.657T >000810.SE

19.02.2026 г., 23:37 ч. UTC

Пазарно говорене

Gold Edges Lower on Possible Position Adjustment -- Market Talk

19.02.2026 г., 23:34 ч. UTC

Печалби

Samsung Fire & Marine Insurance 4Q Net Profit Missed FactSet-Compiled Consensus

19.02.2026 г., 23:34 ч. UTC

Печалби

Samsung Fire & Marine Insurance 4Q Net KRW234.38B Vs. Net KRW207.88B >000810.SE

19.02.2026 г., 23:33 ч. UTC

Печалби

Samsung Fire & Marine Insurance 4Q Oper Pft KRW391.26B Vs. Pft KRW252.81B >000810.SE

19.02.2026 г., 23:33 ч. UTC

Печалби

Samsung Fire & Marine Insurance 4Q Rev KRW6.083T Vs. KRW6.297T >000810.SE

19.02.2026 г., 22:13 ч. UTC

Пазарно говорене

Goodman's Lack of Earnings Upgrade 'Largely Timing Related' -- Market Talk

19.02.2026 г., 22:08 ч. UTC

Печалби

Fairfax Financial 4Q Rev $8.11B >FFH.T

19.02.2026 г., 22:07 ч. UTC

Печалби

Eldorado Gold 4Q EPS $1.19 >ELD.T

19.02.2026 г., 22:06 ч. UTC

Печалби

Centerra Gold: 2026 Consolidated Gold Production Expected 250,000 to 280,000 Ounces, Copper Production Expected 50M to 60M Pounds >CG.T

19.02.2026 г., 22:05 ч. UTC

Печалби

Eldorado Gold 4Q Adj EPS 63c >ELD.T

19.02.2026 г., 22:05 ч. UTC

Печалби

Eldorado Gold 4Q Rev $577.2M >ELD.T

19.02.2026 г., 22:04 ч. UTC

Печалби

Eldorado Gold 4Q Gold Sales 126,923 Ounces >ELD.T

19.02.2026 г., 22:04 ч. UTC

Печалби

Eldorado Gold 4Q Gold Production 123,416 Ounces >ELD.T

19.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

19.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

19.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

19.02.2026 г., 21:43 ч. UTC

Печалби

St Barbara 1H Underlying Profit A$1.3 Million Vs A$48.1 Million Loss Year Earlier

19.02.2026 г., 21:42 ч. UTC

Придобивния, сливания и поглъщания

Palo Alto Networks Announces Offer to Purchase Relating to CyberArk Software Ltd.'s 0.00% Convertible Senior Notes Due 2030

19.02.2026 г., 21:42 ч. UTC

Печалби

St Barbara 1H Revenue A$128.8 Million, Up 32% On-Year

19.02.2026 г., 21:41 ч. UTC

Печалби

Correct: St Barbara 1H Net Loss A$249,000

19.02.2026 г., 21:40 ч. UTC

Печалби

St Barbara 1H Net Loss A$249 Million

19.02.2026 г., 21:39 ч. UTC

Печалби

Perseus Mining Reaffirms FY26 Production, AISC Guidance

19.02.2026 г., 21:37 ч. UTC

Печалби

These Stocks Are Today's Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More -- Barrons.com

19.02.2026 г., 21:37 ч. UTC

Печалби

Century Aluminum Expects 1Q Adj EBITDA $215 M to $235 M >CENX

Сравнение с други в отрасъла

Ценова промяна

Xenon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

29.38% нагоре

12-месечна прогноза

Среден 55 USD 29.38%

Висок 66 USD

Нисък 44 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Xenon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Xenon Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

34.81 / 38.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

165 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.